InsiderSignal.AI

InsiderSignal.ai

RARE - Ultragenyx Pharmaceutical Inc.

Insider Sale by Horn Howard (CFO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

4 days ago, Horn Howard, serving as CFO at Ultragenyx Pharmaceutical Inc. (RARE), sold 4,683 shares at $20.97 per share, for a total transaction value of $98,203.00. Following this transaction, Horn Howard now holds 80,351 shares of RARE.

This sale represents a 6.00% decrease in Horn Howard's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Wednesday, April 1, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, April 2, 2026, 1 day after the trade was made.

Ultragenyx Pharmaceutical Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Horn Howard

Horn Howard

CFO

Howard Horn is the Chief Financial Officer and Executive Vice President of Corporate Strategy at Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company developing therapies for rare genetic diseases. He joined in October 2023 and oversees global finance, accounting, corporate strategy, and investor relations.[[1]](https://venturelab.upenn.edu/programs/visiting-experts-ama-howard-horn-cfo-exec-vp-at-ultragenyx)[[2]](https://fintool.com/app/research/companies/RARE/people/howard-horn)[[3]](https://www.ultragenyx.com/leaders/howard-horn/)[[4]](https://www.northbaybusinessjournal.com/article/industrynews/marin-countys-ultragenyx-pharmaceutical-hires-new-chief-financial-officer/) Horn (age 47) previously served as CFO and founding management team member at Vir Biotechnology (2017–2023), leading its transition to a public, commercial-stage company. Earlier roles include Vice President of Strategic Corporate Finance and Business Planning at Biogen, consultant in McKinsey & Company's Pharmaceutical and Medical Products Practice, and equity research analyst at UBS in Life Sciences. He holds a B.A. in Economics from Princeton University and an M.B.A. from the Wharton School (WG'04).[[1]](https://venturelab.upenn.edu/programs/visiting-experts-ama-howard-horn-cfo-exec-vp-at-ultragenyx)[[2]](https://fintool.com/app/research/companies/RARE/people/howard-horn)[[3]](https://www.ultragenyx.com/leaders/howard-horn/)[[4]](https://www.northbaybusinessjournal.com/article/industrynews/marin-countys-ultragenyx-pharmaceutical-hires-new-chief-financial-officer/) Recently, as a corporate insider, Horn sold shares in Ultragenyx, including 3,061 shares on February 2, 2026, for $72,117, and 1,635 shares on March 3, 2026, for $36,624.[[5]](https://au.investing.com/news/insider-trading-news/ultragenyx-rare-cfo-horn-sells-72k-in-stock-93CH-4238333)[[6]](https://www.marketbeat.com/instant-alerts/howard-horn-sells-1635-shares-of-ultragenyx-pharmaceutical-nasdaqrare-stock-2026-03-03/)

View full insider profile →

Trade Price

$20.97

Quantity

4,683

Total Value

$98,203.00

Shares Owned

80,351

Trade Date

Wednesday, April 1, 2026

4 days ago

SEC Filing Date

Thursday, April 2, 2026

Filed 1 day after trade

HEALTHCAREBIOTECHNOLOGY

About Ultragenyx Pharmaceutical Inc.

Company Overview

No company information available
View news mentioning RARE

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5312752

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime